Biocracked
Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
Research

Dosis CBL‑514 – Apa sing Dikatakan Ilmu?

Dr. Synapse · · 4 min read

Dosis CBL‑514 – apa sing diomongake ilmu?

Waca iki dhisik: CBL‑514 iku injeksi investigasional sing diteliti ing uji klinis. Iki dudu dosis oral, dudu suplemen, dudu produk sing wis disetujoni, lan ora ana ing kéné sing dadi rekomendasi. Angka “600 mg” sing kerep nyebar ing internet iku wates maksimum saben perawatan ing protokol uji sing diawasi, sing gegandhengan karo volume injeksi, area perawatan, lan jadwal tartamtu. Iku dudu ukuran porsi. (Cathetan ejaane: CBL‑514, dudu “CL‑514”.)

CBL‑514 asalé saka Caliway Biopharmaceuticals lan diterangaké minangka agen injeksi molekul cilik kanggo lipolisis. Ing makalah, diwènèhaké minangka injeksi subkutan ing weteng déning peneliti uji. Mekanisme sing diusulake, adhedhasar kerja non‑klinis sing disitasi saka laporan perusahaan sing ora dipublikasikaké, yaiku apoptosis sel lemak (adiposit). Iku dudu ningkataké tingkat metabolisme, dudu “pembakaran lemak” sacara sistemik, lan dudu penurunan bobot awak sakabèhé. Makalah ora nerangaké struktur kimia molekul kasebut.

Langkah siji: studi fase 2a golek dosis

Studi sing luwih dhisik yaiku Goodman et al., Aesthetic Surgery Journal 2022 (PMC9384315). Iki open‑label tanpa plasebo, lan cilik: n=43, dipérang 7 / 18 / 18 ing telung tingkat dosis.

Dosis unit diungkapaké saben sentimeter persegi kulit sing diobati, ing area 150 cm²:

Tingkat Dosis Total per sesi (150 cm²)
1,2 mg/cm² 180 mg
1,6 mg/cm² 240 mg
2,0 mg/cm² 300 mg

Sesi nggunakake maksimal 60 injeksi saben 2 minggu. Angka mg mung konsentrasi per area dikalikan karo area. Contone, 2,0 mg/cm² × 150 cm² = 300 mg.

Makalah nglaporaké persentase pengurangan (intention‑to‑treat, ITT) kanggo saben grup dosis, lan para pamaca kudu mripataké makalah kanggo angka‑angka kuwi. Angka sing paling asring disebut yaiku 24,96 %. Iku asil per‑protocol (PP) kanggo grup 2,0 mg/cm², ing follow‑up pertama, sing cocog karo ‑119,82 mL volume lemak. Angka PP iku subset sing ngétung peserta sing tundhuk banget marang protokol. Iku ora kudu dianggep minangka asil utama kanggo kabeh sing melu.

Langkah loro: fase 2 kontrol plasebo

Makalah utama yaiku Gold et al., Aesthetic Surgery Journal 2025;45(6):611‑620 (PMC12080885; PubMed; DOI). Iki randomisasi, single‑blind (mung peserta sing diblind), lan kontrol plasebo; ditindakake ing lima pusat ing AS lan Australia.

Dosis unit tetep 2,0 mg/cm². Kabeh liyane diubah:

  • Area perawatan: 300 cm² (kapindho ukuran fase 2a).
  • Injeksi: 25‑50 injeksi saben perawatan, gumantung marang jumlah lemak weteng sing ditemokaké.
  • Saben injeksi: 2,4 mL, dipisah 2,45 cm.
  • Batas maksimal: nganti 600 mg per perawatan (2,0 mg/cm² × 300 cm²).
  • Jadwal: nganti 4 perawatan saben 4 minggu, kanthi follow‑up ing 4 lan 8 minggu sawisé perawatan pungkasan.
  • Kontrol: saline normal ing volume sing padha.

Pembandingé yaiku plasebo saline, randomisasi 2 : 1.

Napa total mg ora bisa dipertukarke

Lonjakan saka 300 mg dadi 600 mg ora ateges dosis “dobel” ing arti biologis apa wae. Dosis per area tetep padha, 2,0 mg/cm². Mung wilayah sing diobati sing tambah gedhé. Antarane loro studi, area, jumlah injeksi maksimal, interval antar sesi, lan desain studi kabeh béda. Total mg mung nduwéni arti yen digandhengaké karo area, volume saben injeksi, jarak, jadwal, lan sapa sing nglakokaké.

Mula maca “600 mg” kaya dosis suplemen iku nyasar. Angka kasebut mung nuduhaké wates maksimal kanggo seri injeksi adhedhasar area sing diwènèhi déning klinisi. Iku ora ngandharaké apa sing bakal diserep utawa ditoleransi déning individu njaba kerangka kasebut.

Ora ana perbandingan langsung dosis unit ing fase 2

Fase 2 ora randomisasi peserta menyang dosis unit sing béda‑bèda kanthi kontrol plasebo. 2,0 mg/cm² dipilih adhedhasar karya sadurungé. Dadi bukti kontrol plasebo mung ndhukung siji protokol, ora kurva dosis‑respons. Perbandingan multi‑dosis mung ana ing studi open‑label cilik fase 2a, sing ora nduwéni lengan plasebo.

Apa sing ditemokake fase 2 ing protokol kuwi

Penulis nglaporaké yen studi iki nyukupi endpoint primer lan sekunder. Ing analisis ITT, 63,9 % (23/36) peserta CBL‑514 ilang paling ora 150 mL volume lemak subkutan ing follow‑up 4 minggu, dibandhingake karo 17,4 % (4/23) ing plasebo. Ing 8 minggu, persentase iku 69,6 % (16/23) vs 0,0 % (0/16). Denominator suda amarga data follow‑up ilang.

Rata‑rata beda antar kelompok (least‑squares mean) yaiku ‑206,62 mL ing 4 minggu lan ‑216,28 mL ing 8 minggu. Volume lemak diprakirakaké saka ultrasound ing papat titik lan area 300 cm², dudu diukur langsung.

Cathetan penting:

  • Saka 75 peserta sing diobati, 37 ora ngrampungaké studi (49,3 %).
  • Populasi PP mung 30 wong.
  • Sponsor melu ing desain, analisis, lan nulis.
  • Peneliti ora diblind.
  • Ukuran sampel eksploratori.
  • Bobot awak ora owah sacara signifikan, mula iki pengurangan volume lemak lokal, dudu penurunan bobot.

Keamanan ing dosis trial

Keamanan dilacak liwat kejadian ala (adverse events) sing muncul sawise perawatan, laboratorium, vital, ECG, pemeriksaan fisik, lan reaksi situs injeksi sing dicathet minangka kejadian terpisah saben perawatan. Reaksi lokal ing situs injeksi dadi temuan utama amarga protokol nglibatké puluhan injeksi saben sesi. Pamaca kudu mriksa makalah kanggo angka insiden sing tepat, kalebu tingkat rasa sakit parah, tinimbang ngandelaké rangkuman. Papat saka 37 peserta sing ora ngrampungaké ing fase 2 metu amarga kejadian ala.

Ing fase 2a, tim studi nggunakake anestesi, es, lan antihistamin. Iku praktek studi, dudu saran. Iku nerangaké kepiye peneliti ngatur prosedur investigasional, dudu apa sing kudu dilakoni déning sapa wae.

Makalah uga nyathet sinyal lipid ing sawetara peserta sing nduwéni lipid dasar dhuwur. Iku observasi ing jumlah cilik wong, lan ora dadi profil efek samping metabolik sing terbukti. Ora ana ing trial iki sing netepaké efek sistemik CBL‑514.

Kesimpulan kanggo biohacker

Ilmu bab dosis CBL‑514 iku sempit lan spesifik. Studi open‑label cilik mbandhingaké telung dosis per area, lan uji single‑blind sing luwih gedhé tetep nganggo siji (2,0 mg/cm²) ing area luwih gedhé karo wates maksimal per sesi luwih dhuwur. Nganggep “600 mg” minangka dosis label bakal nglirwakaké kabeh iki.

CBL‑514 ora disetujoni, ora produk konsumen, lan artikel iki ora dadi saran medis.

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 1, macro science, in palette D, bold color field.

Extreme close-up photograph of a cluster of fat cells (adipocytes) in tissue, shot like a stained microscopy image. Rounded, translucent, pearly-yellow lipid-filled cells press together in a honeycomb. Several in the center look collapsed and shriveled, with ruptured membranes and scattered droplets. A few fine threads of electric green (#00e676) fluorescent stain outline the cell walls. The camera is straight-on at shallow depth of field, with the background cells melting into soft blur. Bright, even transmitted light makes the membranes glow. The backdrop is a saturated magenta-to-tomato-red field that sets off the pale yellow cells. The mood is scrutinizing, skeptical and precise. No text, no labels.
research

Injeksi Penghilangan Lemak CBL-514: Apa Kata Ilmu?

BY DR. SYNAPSE ·

CBL-514 saiki wis liwat uji coba acak fase 2 sing dikontrol plasebo lan diterbitaké ing *Aesthetic Surgery Journal*. Penulis nglaporaké yèn uji iki nyukupi titik akhir utama lan sekunder, nanging desainé duwé akèh kekurangan: mung siji‑blind, sponsor melu ngrancang, nganalisa, lan nulis studi, lan tingkat drop‑out meh separo. Saka 75 peserta sing mlebu, mung 38 sing rampung, lan populasi sing diteliti mayoritas wanita lan kulit putih. Ing ngisor iki apa sing bisa didhukung uji iki, apa sing ora, lan kenapa iki dudu saran medis utawa bukti perawatan sing wis disetujui.

Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
research

Injeksi Lipolisis CBL-514: Peta Bukti Fase II

BY DR. SYNAPSE ·

CBL-514 yaiku suntikan molekul cilik sing lagi diteliti supaya sel lemak (adiposit) ngalami apoptosis lan njalari pangurangan kantong lemak ing weteng. Ing uji fase II sing dilakokaké ing taun 2025 kanthi 76 peserta acak, volume lemak sing diukur nganggo ultrasound nyusut drastis dibandhingake karo saline, nanging bobot awak ora owah. Tulisan iki nerangake desain, dosis 2 mg/cm², data efektifitas lengkap karo denominator sing saya cilik, lan mekanisme DYRK1b‑caspase sing dilaporaké perusahaan. Nanging uga disorot watesan penting: desain siji‑blind, peran sponsor, attrisi 49 %, follow‑up sing cekak, lan mayoritas partisipan wanita.

**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
research

Kepiye Cara Kerja CBL-514? Iki Ilmu Penjenengané

BY DR. SYNAPSE ·

CBL-514 ora dianggep minangka obat sing nglebur lemak. Klaimé ngganggu sinyal urip sel lemak lan nyurung sel kasebut mlebu proses apoptosis liwat DYRK1b, caspase‑3 lan Bax/Bcl‑2. Buktine asalé saka laporan perusahaan sing durung dipublikasikaké, dene struktur kimiane ora diwartakake. Uji fase 2 taun 2025 mung ngukur volume lemak nganggo ultrasonik lan foto, tanpa biopsi utawa data caspase. Artikel iki misahaké hipotesis molekuler saka apa sing saktenané diukur ing manungsa, kalebu tingkat dropout sing dhuwur lan rancangan single‑blind.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Apa CBL‑514 Tenan Ngobong Lemak? Kabeh Sing Kita Ngerti

BY HELIX WARD ·

Uji coba fase 2 CBL‑514 ing taun 2025 ora ngukur penurunan bobot awak, nanging nyoba apa suntikan langsung menyang jaringan lemak ing weteng bisa ngurangi paling ora 150 mL volume lemak subkutan sing diukur nganggo ultrasonik. Sawisé wolung minggu, 69,6 % (16 saka 23) partisipan sing nampa CBL‑514 nganti target iki, dene kelompok plasebo ora ana sing nggayuh. Nanging rata‑rata bobot awak malah ora mudhun (+0,02 kg), separo partisipan ora ngrampungake studi, lan jumlah partisipan sing netepi protokol mung 30 wong. Reaksi situs suntikan umum, kaya owah‑warna (71,4 %) lan rasa lara sing serius (18,4 %).

This page is available in